HAE logo

Haemonetics Corporation Stock Price

NYSE:HAE Community·US$2.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author

HAE Share Price Performance

US$50.49
-27.40 (-35.18%)
53.2% undervalued intrinsic discount
US$107.86
Fair Value
US$50.49
-27.40 (-35.18%)
53.3% undervalued intrinsic discount
US$108.00
Fair Value
Price US$50.49
AnalystHighTarget US$108.00
AnalystConsensusTarget US$78.64
AnalystLowTarget US$65.50

HAE Community Narratives

AnalystHighTarget·Updated
Fair Value US$107.86 53.2% undervalued intrinsic discount

Secular Trends Will Fuel Expansion In Blood Management Solutions

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value US$78.64 35.8% undervalued intrinsic discount

Aging Demographics Will Expand Global Plasma And Hemostasis Markets

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AnalystLowTarget·Updated
Fair Value US$58 12.9% undervalued intrinsic discount

Regulatory Pressures And Competition Will Restrict Plasma But Reveal Value

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent HAE News & Updates

Is Haemonetics Corporation (NYSE:HAE) Trading At A 48% Discount?

Sep 15
Is Haemonetics Corporation (NYSE:HAE) Trading At A 48% Discount?

I'm Recommending Haemonetics Again, But With Caveats (Ratings Upgrade)

Aug 11

Market Cool On Haemonetics Corporation's (NYSE:HAE) Earnings Pushing Shares 27% Lower

Aug 08
Market Cool On Haemonetics Corporation's (NYSE:HAE) Earnings Pushing Shares 27% Lower

Haemonetics (NYSE:HAE) Seems To Use Debt Quite Sensibly

Jun 30
Haemonetics (NYSE:HAE) Seems To Use Debt Quite Sensibly

Market Participants Recognise Haemonetics Corporation's (NYSE:HAE) Earnings

Jun 10
Market Participants Recognise Haemonetics Corporation's (NYSE:HAE) Earnings

Do Haemonetics' (NYSE:HAE) Earnings Warrant Your Attention?

May 10
Do Haemonetics' (NYSE:HAE) Earnings Warrant Your Attention?

Haemonetics Corporation Key Details

US$1.3b

Revenue

US$554.9m

Cost of Revenue

US$791.1m

Gross Profit

US$627.8m

Other Expenses

US$163.3m

Earnings

Last Reported Earnings
Jun 28, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
3.39
Gross Margin
58.77%
Net Profit Margin
12.13%
Debt/Equity Ratio
138.9%

Haemonetics Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Undervalued with solid track record.

1 Risk
4 Rewards

About HAE

Founded
1971
Employees
3023
CEO
Christopher Simon
WebsiteView website
www.haemonetics.com

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 1.2%
  • 3 Months: 7.7%
  • 1 Year: 17.9%
  • Year to Date: 14.9%
The market has climbed 1.2% in the last 7 days, lead by the Information Technology sector with a gain of 2.4%. As for the past 12 months, the market is up 18%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›